Fitzgerald Joseph Michael's Form 4 filing
Boston Scientific CorpBSX · filed Jul 2, 2025
- Accession no.
- 0001225208-25-006331
- Filed
- Jul 2, 2025
- Trade date
- Jul 1, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.35M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fitzgerald Joseph MichaelCIK 0001484186 | Officer (EVP & Group Pres, Cardiology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | Common Stock | MOption exerciseAcquired | +50,000 | $26.15 | +$1,307,500 | 228,342 | Direct | |
| Jul 1, 2025 | Common Stock | SSaleDisposed | −50,000 | $106.97F2 | −$5,348,500 | 178,342 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 200,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $106.66 to $107.37, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.